Business Context and Reporting Period
This Form 8-K is a current report filed by Ventrus Biosciences, Inc. (noted as Assembly Biosciences in metadata) on February 7, 2013. The filing addresses a corporate event related to the company's recent public stock offerings.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, or cash flow data. The specific financial details disclosed are:
- Transaction Type: Full exercise of an over-allotment option by the underwriter.
- Shares Issued: 870,000 additional shares of common stock.
- Price Per Share: $2.50 (less underwriting discount, commissions, and offering expenses).
- Related Offerings: Concurrent Series A Non-Voting Convertible preferred stock public offering.
- Closing Date of Initial Offering: February 4, 2013.
Material Changes
The material change reported is the increase in the number of common shares outstanding due to the full exercise of the over-allotment option. This event occurred immediately following the closing of the initial public offering on February 4, 2013.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, or specific risk factors beyond the standard disclosure of the stock issuance event. No unusual items or contingencies are described in the text provided.
Investor Verification Checklist
- Verify the total capital raised by calculating the net proceeds from the 870,000 shares at $2.50 per share after deducting underwriting fees.
- Confirm the updated total share count of common stock outstanding post-exercise.
- Review the attached press release (Exhibit 99.1) for details on the use of proceeds.
- Check subsequent filings for the final closing details of the concurrent Series A Non-Voting Convertible preferred stock offering.